Meridian Bioscience Inc. (VIVO) Given Average Rating of “Hold” by Brokerages
Shares of Meridian Bioscience Inc. (NASDAQ:VIVO) have been given an average recommendation of “Hold” by the seven analysts that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $11.50.
A number of research firms have recently issued reports on VIVO. Zacks Investment Research downgraded shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Canaccord Genuity reiterated a “hold” rating and set a $14.00 price target on shares of Meridian Bioscience in a research report on Friday, October 13th. Finally, BidaskClub downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Thursday, July 6th.
In related news, Chairman John A. Kraeutler purchased 7,000 shares of Meridian Bioscience stock in a transaction dated Thursday, August 24th. The stock was bought at an average cost of $13.67 per share, for a total transaction of $95,690.00. Following the transaction, the chairman now owns 345,230 shares in the company, valued at $4,719,294.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.30% of the stock is currently owned by company insiders.
Shares of Meridian Bioscience (VIVO) opened at 14.50 on Wednesday. The firm’s 50-day moving average price is $14.45 and its 200 day moving average price is $14.44. Meridian Bioscience has a 1-year low of $10.75 and a 1-year high of $18.58. The stock has a market capitalization of $611.94 million, a price-to-earnings ratio of 29.00 and a beta of 0.84.
Meridian Bioscience (NASDAQ:VIVO) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.16. Meridian Bioscience had a net margin of 10.77% and a return on equity of 16.93%. The company had revenue of $50.14 million during the quarter, compared to the consensus estimate of $49.13 million. During the same period last year, the firm earned $0.21 EPS. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. Equities research analysts expect that Meridian Bioscience will post $0.68 earnings per share for the current fiscal year.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.